We are monitoring the impact of COVID-19 & Recession alarm on MEA ADHD Therapeutics Market Get in touch with us for detailed analysis Know More
Share on

Middle East & Africa Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Research Report – Segmented By Treatment, Medication, Psychotherapy, Education or Training & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) – Industry Size, Share, Trends, Growth & Forecasts (2022 to 2027)

Published: January, 2022
ID: 269
Pages: 145

MEA ADHD Therapeutics Market Size (2022 to 2027)

The Middle East and Africa ADHD Therapeutics Market is expected to reach USD 1.42 billion by 2027 from USD 0.91 billion in 2022, growing at a CAGR of 9.31% during the forecast period.

The healthcare industry is expected to be ruled by technology-driven innovation in the future. As a result, extensive research is being undertaken in every healthcare market sector, with precision medicine serving as the focal point.

ADHD children are more likely to develop a range of additional issues, such as clinical depression. In addition, due to their warped lifestyle and inability to control their urges, these children may develop long-term psychiatric disorders. As a result, it's vital to create effective ADHD therapies for children and teenagers. Furthermore, the growing focus of the medical community on the treatment of mental illnesses is expected to boost market growth.

The prevalence and incidence of attention-deficit hyperactivity disorder among adults and children in MEA are estimated to accelerate the market's growth during the forecast period. Furthermore, countries such as the United Arab Emirates (UAE) and Kuwait, where key companies are focusing on research and development in the treatment of attention deficit hyperactivity disorder (ADHD), are expected to drive the Therapeutics for attention deficit hyperactivity disorder (ADHD) in MEA during the forecast period.

However, prescriptions are limited based on a patient's medical condition due to many contraindications and harmful effects of ADHD drugs, which is expected to slow revenue growth.

This research report on the MEA ADHD therapeutics market has been segmented and sub-segmented into the following categories:

By Medication:

  • Stimulants
  • Non-Stimulants

By Psychotherapy:

  • Behaviour Therapy
  • Cognitive Behavioural Therapy
  • Interpersonal Psychotherapy
  • Family Therapy

By Education Or Training:

  • Parent Management Training
  • Social Skills Training
  • School-Based Interventions

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

During the forecast period, the demand for ADHD drugs in the MEA is expected to expand. The healthcare industry is working hard to provide viable treatment options for ADHD in children and adolescents. Because of the detrimental implications of ADHD, medical experts have decided to focus their efforts on finding new treatment alternatives.

A thorough examination of the regional market for ADHD therapies uncovers a host of factors that have influenced regional demand. In the UAE and Kuwait, attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by debilitating and pervasive impulsivity, hyperactivity, and inattention symptoms.

KEY MARKET PLAYERS:

Shire plc (Ireland), Neos Therapeutics, Inc. (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Alcobra Ltd. (Israel), Supernus Pharmaceuticals, Inc. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson (U.S.) and Curemark, LLC. (U.S.) are a few of the prominent companies in the MEA ADHD therapeutics market.

  1. Introduction

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                          

                1.4 General Study Assumptions                                

  1. Research Methodology

                2.1 Introduction                                               

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                           

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                      

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

  1. Overview

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                               

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                                              

  1. Market Segmentation

                5.1 Introduction                                               

                5.2 Treatment By Medication                                    

                                5.2.1 Introduction                           

                                5.2.2 Stimulants                               

                                                5.2.2.1 Introduction       

                                                5.2.2.2 Amphetamines 

                                                5.2.2.3 Methylphenidate             

                                                5.2.2.4 Dextroamphetamine      

                                                5.2.2.5 Dexmethylphenidate     

                                5.2.3 Non-Stimulants                     

                                                5.2.3.1 Introduction       

                                                5.2.3.2 Atomoxetine      

                                                5.2.3.3 Bupropion           

                                                5.2.3.4 Guanfacine         

                5.3 Treatment By Psychotherapy                                             

                                5.3.1 Introduction                           

                                5.3.2 Behavior Therapy                 

                                5.3.3 Cognitive Behavioral Therapy                         

                                5.3.4 Interpersonal Psychotherapy                         

                                5.3.5 Family Therapy                      

                5.4 Treatment By Education or Training                                 

                                5.3.1 Introduction                           

                                5.3.2 Parent Management Training                         

                                5.3.3 Social Skills Training                             

                                5.3.4 School-Based Interventions                            

  1. Geographical Analysis

                6.5.1 Introduction                                           

                6.5.2 Middle East                                             

                6.5.2 Africa                                            

  1. Strategic Analysis

                7.1 PESTLE analysis                                         

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                       

                7.2 Porter’s Five analysis                                              

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services                              

                                7.2.5 Competitive Rivalry within the Industry                     

  1. Market Leaders' Analysis

                8.1 Shire plc (Ireland)                                    

                                8.1.1 Overview                 

                                8.1.2 Product Analysis                   

                                8.1.3 Strategic Evaluation and Operations                            

                                8.1.4 Financial analysis                  

                                8.1.5 Legal issues                             

                                8.1.6 Recent Developments                       

                                8.1.7 SWOT analysis                       

                                8.1.8 Analyst View                          

                8.2 Neos Therapeutics, Inc. (U.S.)                                            

                8.3 Eli Lilly and Company (U.S.)                                  

                8.4 Pfizer Inc. (U.S.)                                       

                8.5 Alcobra Ltd. (Israel)                                 

                8.6 Supernus Pharmaceuticals, Inc. (U.S.)                                            

                8.7 Noven Pharmaceuticals, Inc. (U.S.)                                  

                8.8 Novartis AG (Switzerland)                                    

                8.9 Johnson & Johnson (U.S.)                                    

                8.10 Curemark, LLC., (U.S.)                                         

  1. Competitive Landscape

                9.1 Market share analysis                                            

                9.2 Merger and Acquisition Analysis                                       

                9.3 Agreements, collaborations and Joint Ventures                                         

                9.4 New Product Launches                                         

  1. Expert Opinions

                10.1 Market Outlook                                     

                10.2 Investment Opportunities                                 

     Appendix                                                          

a) List of Tables

b) List of Figures

  1. Middle East & Africa Attention-Deficit Hyperactivity Disorder Therapeutics Market By Region, From 2022 - 2027 (USD Billion)
  2. Middle East & Africa Attention-Deficit Hyperactivity Disorder Therapeutics Market By Medication, From 2022 - 2027 (USD Billion)
  3. Middle East & Africa Stimulants Market By Region, From 2022 - 2027 (USD Billion)
  4. Middle East & Africa Non-Stimulants Market By Region, From 2022 - 2027 (USD Billion)
  5. Middle East & Africa Attention-Deficit Hyperactivity Disorder Therapeutics Market By Psychotherapy, From 2022 - 2027 (USD Billion)
  6. Middle East & Africa Behavior Therapy ADHD Therapeutics Market By Region, From 2022 - 2027 (USD Billion)
  7. Middle East & Africa Cognitive Behavioral Therapy ADHD Therapeutics Market By Region, From 2022 - 2027 (USD Billion)
  8. Middle East & Africa Interpersonal Psychotherapy ADHD Therapeutics Market By Region, From 2022 - 2027 (USD Billion)
  9. Middle East & Africa Family Therapy ADHD Therapeutics Market By Region, From 2022 - 2027 (USD Billion)
  10. Middle East & Africa Attention-Deficit Hyperactivity Disorder Therapeutics Market By Education or Training, From 2022 - 2027 (USD Billion)
  11. Middle East & Africa Parent Management Training ADHD Therapeutics Market By Region, From 2022 - 2027 (USD Billion)
  12. Middle East & Africa Social Skills Training ADHD Therapeutics Market By Region, From 2022 - 2027 (USD Billion)
  13. Middle East & Africa School-based Interventions ADHD Therapeutics Market By Region, From 2022 - 2027 (USD Billion)
  14. Middle East Attention-Deficit Hyperactivity Disorder Therapeutics Market By Medication, From 2022 - 2027 (USD Billion)
  15. Middle East Attention-Deficit Hyperactivity Disorder Therapeutics Market By Psychotherapy, From 2022 - 2027 (USD Billion)
  16. Middle East Attention-Deficit Hyperactivity Disorder Therapeutics Market By Education or Training, From 2022 - 2027 (USD Billion)
  17. Africa Attention-Deficit Hyperactivity Disorder Therapeutics Market By Medication, From 2022 - 2027 (USD Billion)
  18. Africa Attention-Deficit Hyperactivity Disorder Therapeutics Market By Psychotherapy, From 2022 - 2027 (USD Billion)
  19. Africa Attention-Deficit Hyperactivity Disorder Therapeutics Market By Education or Training, From 2022 - 2027 (USD Billion)
  20. Middle East & Africa Stimulants ADHD Therapeutics Market By Type, From 2022 - 2027 (USD Billion)
  21. Middle East & Africa Amphetamines Market By Region, From 2022 - 2027 (USD Billion)
  22. Middle East & Africa Methylphenidate Market By Region, From 2022 - 2027 (USD Billion)
  23. Middle East & Africa Dextroamphetamine Market By Region, From 2022 - 2027 (USD Billion)
  24. Middle East & Africa Dexmethylphenidate Market By Region, From 2022 - 2027 (USD Billion)
  25. Middle East Stimulants ADHD Therapeutics Market By Type, From 2022 - 2027 (USD Billion)
  26. Africa Stimulants ADHD Therapeutics Market By Type, From 2022 - 2027 (USD Billion)
  27. Middle East & Africa Non-Stimulants ADHD Therapeutics Market By Type, From 2022 - 2027 (USD Billion)
  28. Middle East & Africa Atomoxetine Market By Region, From 2022 - 2027 (USD Billion)
  29. Middle East & Africa Bupropion Market By Region, From 2022 - 2027 (USD Billion)
  30. Middle East & Africa Guanfacine Market By Region, From 2022 - 2027 (USD Billion)
  31. Middle East Non-Stimulants ADHD Therapeutics Market By Type, From 2022 - 2027 (USD Billion)
  32. Africa Non-Stimulants ADHD Therapeutics Market By Type, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

2875


pdf excel
$

3220


pdf excel powerbi
$

4600


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2875

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample